prodchem
Aug 28, 2026
Clariant's recent CFO transition provides an interesting benchmark for how specialty chemical companies are refreshing financial leadership during a period of weak demand, high energy costs and intense global competition. The company appointed Oliver Rittgen as CFO effective August 1, 2025, succeeding Bill Collins, who retired after three years in the role. Rittgen joined from Bayer, where he spent nearly 25 years in senior management and most recently served as CFO of the Crop Science division.
Rittgen's background gives Clariant a CFO with extensive experience managing complex international businesses rather than a traditional specialty-chemicals-only career. Before joining Clariant, he held several senior finance positions at Bayer, including CFO roles in Crop Science and Consumer Health. That experience is particularly relevant as Clariant manages cost pressures, portfolio decisions and regional differences across its three businesses: Care Chemicals, Catalysts, and Adsorbents & Additives.
The company has previously demonstrated that its finance leadership can move successfully between industries. Patrick Jany served as Clariant's CFO for approximately 14 years before leaving in 2020 to become CFO of A.P. Moller–Maersk. Clariant then appointed Stephan Lynen as his successor. The history illustrates how senior finance talent from specialty chemicals can transfer into other complex multinational industries—and how external experience can subsequently flow back into chemical companies.
Clariant's leadership transition comes against a difficult operating backdrop. The company is targeting CHF 80 million in savings by 2027, with CHF 50 million already achieved, while continuing to face weak demand, high European energy costs, tariffs and competition from China. In its 2026 outlook, Clariant expects only a slight improvement in its core profit margin, making financial discipline and cost management particularly important for its CFO.
The broader specialty-chemicals sector is also undergoing strategic changes as companies respond to muted industrial demand and margin pressure. European chemical companies including Clariant, Solvay and dsm-firmenich have relied heavily on restructuring and efficiency programs in 2026. This makes CFO appointments more significant than routine executive succession: finance chiefs increasingly have to manage restructuring, capital allocation, pricing discipline and cost reduction simultaneously.
The key benchmark is therefore not simply how long a CFO stays in the position, but what type of financial expertise specialty chemical companies are seeking. Clariant's choice of an experienced Bayer executive reflects a preference for broad multinational finance and transformation experience. Combined with its earlier example of Patrick Jany moving from Clariant to Maersk, the company provides an interesting case study of how CFO talent circulates across major industrial sectors during periods of strategic change.
Featured Product
Found this useful?
Continue Reading
Clariant's CFO leadership transition, from interim coverage to permanent appointment, highlights the governance and disclosure processes required during major executive changes. The transition also offers lessons for procurement teams and chemical suppliers monitoring leadership shifts.
Product stewardship in 2026 hinges on substituting persistent bioaccumulative and toxic compounds. This analysis quantifies the reformulation cost curve and timeline pressure from REACH-adjacent restrictions.
Regeneron's successful navigation of the FDA's newer national priority voucher program for Otarmeni provides a working precedent for the developing regulatory pathway. The approval also offers lessons for pharmaceutical companies planning manufacturing, procurement and commercial launch activities around accelerated review.
